Canine and Feline Epilepsy. Luisa De Risio
poisoning of a dog by incorporation in ground meat. Journal of Medical Toxicology: Official Journal of American College of Medical Toxicology 8(4), 436–440.
Thomas, D.E., Lee, J.A. and Hovda, L.R. (2012) Retrospective evaluation of toxicosis from selective serotonin reuptake inhibitor antidepressants: 313 dogs (2005-2010). Journal of Veterinary Emergency and Critical Care 22(6), 674–681.
Thompson, J.P., Senior, D.F. and Pinson, D.M. (1987) Neurotoxicosis associated with the use of hexachlorophene in a cat. Journal of American Veterinary Medical Association 190, 1311–1312.
Thrall, M.A., Connally, H.E., Grauer, G.F. and Hamar, D. (2006) Ethylene glycol. In: Peterson, P.E., Talcott, P.A. (eds) Small Animal Toxicology, 2nd edn. Elsevier Saunders, St Louis, Missouri, pp. 702–726.
Tisdall, P., Hunt, G.B., Youmans, K.R. and Malik, R. (2000) Neurological dysfunction in dogs following attenuation of congenital extrahepatic portosystemic shunts. Journal of Small Animal Practice 41, 539–546.
Torisu, S., Washizu, M., Hasegawa, D. and Orima, H. (2005) Brain magnetic resonance imaging characteristics in dogs and cats with congenital portosystemic shunts. Veterinary Radiology and Ultrasound 46(6), 447–451.
Van Hee, P., Neels, H., De Doncker, M., Vrydags, N., Schatteman, K., Uyttenbroeck, W., Hamers, N., Himpe D. and Lambert, W. (2004) Analysis of gamma-hydroxybutyric acid, DL-lactic acid, glycolic acid, ethylene glycol and other glycols in body fluids by a direct injection gas chromatography-mass spectrometry assay for wide use. Clinical Chemistry and Laboratory Medicine 42(11), 1341–1345.
Vandevelde, M., Boring, J.G., Hoff, E.J. and Gingerich, D.A. (1978) The effect of levamisole on the canine central nervous system. Journal of Neuropathology and Experimental Neurology 37, 165–173.
Ward, B., Jones, B. and Rubin, G. (1973) Hexachlorophene toxicity in dogs. Journal of American Animal Hospital Association 9, 167.
Wismer, T. and Means, C. (2012) Toxicology of newer insecticides in small animals. Veterinary Clinics of North America Small Animal Practice 42(2), 335–347.
Wolf, A.M. (1980) Canine uremic encephalopathy. Journal of American Animal Hospital Association 16, 735–738.
Wright, H.M., Chen, A.V., Talcott, P.A., Poppenga, R.H. and Mealey, K.L. (2011) Intravenous fat emulsion as treatment for ivermectin toxicosis in three dogs homozygous for the ABCB1-1β gene mutation. Journal of Veterinary Emergency and Critical Care 21(6), 666–672.
Yas-Natan, E., Segev, G. and Aroch, I. (2007) Clinical, neurological and clinicopathological signs, treatment and outcome of metaldehyde intoxication in 18 dogs. Journal of Small Animal Practice 48(8), 438–443.
Young, K.L., Villar, D., Carson, T.L., Ierman, P.M., Moore, R.A. and Bottoff, M.R. (2003) Tremorgenic mycotoxin intoxication with penitrem A and roquefortine in two dogs. Journal of American Veterinary Medical Association 222(1), 52–53, 35.
Zimmermann, R., Hülsmeyer, V., Sauter-Louis, C. and Fischer, A. (2009) Status epilepticus and epileptic seizures in dogs. Journal of Veterinary Internal Medicine 23(5), 970–976.
Zook, B.C., Carpenter, J.L. and Leeds, E.B. (1967) Lead poisoning in dogs. Journal of American Veterinary Medical Association 155, 1329–1342.
5 Structural Epilepsy
Luisa De Risio Neurology/ Neurosurgery Unit, Centre for Small Animal Studies, Animal Health Trust, Newmarket, UK
Structural epilepsy is caused by a known and identifiable structural forebrain disorder such as vascular, inflammatory/infectious, traumatic, anomalous/developmental, neoplastic and degenerative diseases. Reported prevalence of structural epilepsy in dogs and cats varies among studies ranging from 25–38% in dogs and 34–87% in cats (Quesnel et al., 1997; Bateman and Parent, 1999; Platt and Haag, 2002; Pákozdy et al., 2008; Schriefl et al., 2008; Zimmermann et al., 2009; Steinmetz et al., 2013). Dogs and cats with structural epilepsy usually present with neurological signs (other than seizures) interictally. However, focal lesions in particular areas of the brain (‘clinically silent regions’), such as olfactory bulb, frontal, and pyriform lobes can result in seizure activity without any other neurological signs. In addition, seizures may be the first clinical sign or the only abnormality the pet owner recognizes, at least initially. The signalment, history, disease onset and course and neuroanatomic localization can help to formulate the most appropriate differential diagnosis list. Diagnostic investigations (see Chapter 10) are aimed at identifying the underlying aetiology of the seizures and, if present, of the other neurological signs. Treatment is aimed at the underlying aetiology of the structural brain disease and seizure control with antiepileptic medications (AEMs). Commonly used first-line AEMs are phenobarbital (PB) and potassium bromide (KBr) (see Chapters 12, 13 and 14). Loading or combination with other AEMs with shorter half-lives (such as levetiracetam or zonisamide, see Chapters 15 and 16) may be required to obtain timely clinical efficacy. New generation AEMs may also be used as first-line monotherapy when PB- or Br-related excessive sedation is a concern (e.g. dogs with brain tumours). The choice and dose of the most appropriate AEM is influenced not only by the underlying disease but also by its possible systemic manifestations or concurrent disorders (e.g. PB is contraindicated in animals with hepatic dysfunction; dose reduction of renally excreted AEMs is necessary in animals with impaired renal function). In addition, interactions between AEMs and treatment of the underlying cause of structural epilepsy have to be considered (e.g. in dogs, PB can alter the pharmacokinetics and as a consequence may decrease therapeutic effect of corticosteroids, cyclosporine, metronidazole and other medications) (see Chapter 13). Animals with structural epilepsy may present with cluster seizures or status epilepticus (Bateman and Parent, 1999; Zimmermann et al., 2009). Detailed information on pathophysiology and management of cluster seizures and status epilepticus are presented in Chapter 23 and 24, respectively.
Disease groups resulting in structural epilepsy are presented in order according to the acronym VITAMIN D.
Vascular
Cerebrovascular accidents (ischaemic, haemorrhagic)
Cerebrovascular accidents (CVAs) result from cerebrovascular disease which involves any pathological process of the blood vessels supplying the brain (Wessmann et al., 2009). CVA, also termed stroke, is characterized by non-progressive (or rapidly progressive) intracranial neurological signs with peracute (6 h) to acute (7–24 h) onset and duration of at least 24 h (Victor and Ropper, 2001). When the neurological signs last less than 24 h, the event is referred to as a transient ischaemic attack (TIA) (Victor and Ropper, 2001). TIAs may precede a CVA.
CVAs can be broadly classified as:
• Ischaemic (resulting from occlusion of a cerebral blood vessel by a thrombus or embolism, causing ischaemic necrosis or infarction); and
• Haemorrhagic (resulting from rupture of an intracranial blood vessel wall, causing haemorrhage into or around the brain) (Wessmann et al., 2009; Garosi, 2010).
Ischaemic CVA can be classified by the territory that the affected blood vessel supplies, the size of the vessel (e.g. territorial infarct with large arterial vessel disease, Fig. 5.1a–e; and lacunar infarct with small perforating arterial